Caroline Seymour


Adjuvant CDK4/6 Inhibition Shows Potential in Early HR+/HER2- Breast Cancer, But More Data Are Needed

March 5th 2021

CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.

New Indications in HER2+ Breast Cancer Spark Discussions on Selection, Safety, and Sequencing

March 4th 2021

The KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB trials have changed practice for patients with HER2-positive breast cancer for the better.

Targeted DNA Sequencing Informs Posttransplant Relapse Rates in MDS

March 3rd 2021

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.

Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer

March 3rd 2021

Darolutamide plus ADT will be evaluated versus ADT alone in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE study as part Bayer and Orion Corporation’s growing clinical development program for the oral AR inhibitor in prostate cancer.

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

March 3rd 2021

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.

Armand Reviews Novel Therapeutics in Relapsed/Refractory Follicular Lymphoma

March 2nd 2021

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Raising the Standard Beyond Frontline R-CHOP in DLBCL

February 26th 2021

Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.

Growing Body of Evidence Underscores the Activity and Safety of CAR T-cell Therapy in ALL

February 25th 2021

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

Time-Limited Therapy Takes Center Stage in Frontline and Relapsed/Refractory CLL

February 24th 2021

Fixed-duration treatment that leads to deep treatment-free remissions has become the prioritized strategy for patients with chronic lymphocytic leukemia, made possible by agents such as venetoclax, umbralisib, and lisocabtagene maraleucel.

Schiller Talks TKIs, Treatment Discontinuation, and Transplant in CML

February 23rd 2021

Gary J. Schiller, MD, discusses data from the 2020 ASH Annual Meeting and Exposition and the role of transplant in chronic myeloid leukemia.